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INTRODUCTION
Ovarian cancer is the seventh most common fe-
male cancer worldwide in 2012.1 Each year,
22,280 new cases are diagnosed, leading to 15,500
deaths.2 This cancer is the leading cause of death
among gynecological cancers. There is usually no
Abstract
Objective: To compare the survival and side effects in epithelial
ovarian cancer patients receiving adjuvant chemotherapy of cis-
platin/cyclophosphamide and carboplatin/paclitaxel.
Method: We recruited epithelial ovarian cancer patients receiving
cisplatin/cyclophosphamide (group A) or carboplatin/paclitaxel
(group B) adjuvant chemotherapy after surgery. Chemotherapy was
given for six cycles. Overall survival and side effects were assessed.
Result: A total of 49 patients were recruited, consisting of 25 pa-
tients for group A and 24 patients for group B. In this study, the over-
all survival of stage IC-IV ovarian cancer patients was 37.3 months in
group A (95%CI=31.86-43.46) and 35.5 months (95%CI= 13.93-
43.46) in group B (p<0.001). Hematologic side effects of both groups
were not significantly different, i.e: leukopenia 12% vs 18% (p=0.14)
and thrombocytopenia 5.3% vs 9.7% (p=0.38) in group A and group
B, respectively. Gastrointestinal toxicity occurred more frequently in
group A, i.e: nausea 38.6% vs 22.9% (p<0.05), vomitus 24.6% vs
11.8% (p<0.05) in group A and group B, respectively. Symptoms of
peripheral sensory neuropathy were found in 5.33% of group A sub-
jects and 23.6% of group B (p<0.05).
Conclusion: Overall survival in this study is better in patients receiv-
ing cisplatin/cyclophosphamide than patients receiving carbopla-
tin/paclitaxel. However, further study with larger sample is still
needed. The gastrointestinal side effects are found more frequently
in the cisplatin/cyclophosphamide group, while peripheral sensory
neuropathy and hematologic side effects are more frequent in the
carboplatin/paclitaxel group.
[Indones J Obstet Gynecol 2015; 2: 110-116]
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Abstrak
Tujuan: Membandingkan kesintasan dan efek samping antara pasien
kanker ovarium tipe epitelial yang menerima kombinasi kemoterapi
cisplatin/cyclosphosphamide dengan carboplatin/paclitaxel.
Metode: Pasien kanker ovarium epitelial mendapat ajuvan kemo-
terapi dibagi menjadi dua kelompok berdasarkan jenis obat yang di-
terima; kelompok A yaitu kelompok yang menerima cisplatin/cyclo-
phosphamide, dan kelompok B yaitu kelompok yang menerima car-
boplatin/paclitaxel. Kemoterapi diberikan sebanyak enam siklus. Di-
lakukan penilaian kesintasan dan efek samping masing-masing ke-
lompok.
Hasil: Terdapat 49 pasien dalam penelitian ini, terdiri dari 25 pasien
dalam kelompok A dan 24 pasien dalam kelompok B. Kesintasan kese-
luruhan kanker ovarium stadium IC-IV pada kelompok A yakni 37,3
(IK95%=31,86-43,46) bulan, sedangkan kelompok B yakni 35,5
(IK95%=13,93-43,46) bulan (p<0,001). Efek samping hematologi tidak
berbeda secara signifikan, di mana pada kelompok A didapatkan leu-
kopenia sebanyak 18% dan trombositopenia 9,7%, sedangkan pada
kelompok B sebanyak 12% dan 5,3% (p=0,14 dan 0,38). Toksisitas gas-
trointestinal lebih sering terjadi pada kelompok A, di mana didapat-
kan keluhan mual sebanyak 38,6% dan muntah sebanyak 5,33%, se-
dangkan pada kelompok B sebanyak 22,9% dan 11,8% (p<0,05). Ge-
jala neuropati perifer lebih sering pada kelompok B, yakni sebanyak
23,6% dibandingkan pada kelompok A, yakni 5,33% (p<0,05).
Kesimpulan: Kesintasan keseluruhan secara signifikan lebih baik pa-
da kelompok cisplatin/cyclophosphamide dibandingkan kelompok
carboplatin/paclitaxel. Namun, diperlukan studi lebih lanjut dengan
sampel yang lebih besar. Efek samping sistem gastrointestinal lebih
sering terjadi pada kelompok cisplatin/cyclophosphamide, sedangkan
sistem hematologi dan saraf lebih sering terjadi pada kelompok car-
boplatin/paclitaxel.
[Maj Obstet Ginekol Indones 2015; 2: 110-116]
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symptom in the early stages, and most of the time
symptoms present in an advanced stage. More than
75% of patients present with advanced stage or
stage III-IV according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) classifica-
tion.3-6 In Indonesia, according to the Indonesian
Society of Gynecologic Oncology (INASGO), the in-
cidence of ovarian cancer was 363 cases in 2013.7
More than three decades ago, the standard ad-
juvant chemotherapy treatment of ovarian cancer
in the United States was cisplatin/cyclosphospha-
mide (CC). McGuire et al, held a randomized study
in the Gynecologic Oncology Group (GOG) 111 com-
paring the use of CC and carboplatin/paclitaxel
(CP). The progression-free survival was signifi-
cantly longer (p<0.001) in the CP group compared
to the CC group (median 18 vs 13 months). Overall
survival was also longer (p<0.001) in the CP group
than in the CC group (median 38 vs 24 months).8
Chemotherapy has numerous known side ef-
fects, including bone marrow suppression, liver
disorders, GI tract disorders, renal toxicity, neuro-
toxicity and ototoxicity. Cisplatin generally has
more side effects compared to carboplatin, except
in terms of hematologic effects, especially granulo-
cytopenia and thrombocytopenia. Currently, carbo-
platin and paclitaxel is used as the standard adju-
vant chemotherapy that shows good effectivity and
less side effects, although they are quite expensive
compared to the older regimen of cisplatin and cy-
clophosphamide.
Therapy for epithelial ovarian cancer according
to INASGO guidelines, consists of administration of
50-100 mg/m2 cisplatin or AUC 5-6 carboplatin,
combined with 600 mg/m2 cyclosphosphamide or
175 mg/m2 paclitaxel.9
In Indonesia there is no data on the survival and
side effects of different regimens of chemotherapy
in patients with advanced ovarian cancer. The aim
of this study is to compare the overall survival and
side effects of cisplatin/cyclophosphamide and car-
boplatin/paclitaxel chemotherapy regimens.
METHODS
This historical cohort study’s target population
were patients with stage IC-IV epithelial ovarian
cancer who presented to Dr. Cipto Mangunkusumo
Hospital gynecologic oncology clinic, from January
1st 2008 to December 1st 2013.
We included all patients with stage IC-IV ovarian
cancer patients who have undergone surgery and
received adjuvant chemotherapy of cisplatin and
cyclophosphamide or carboplatin and paclitaxel,
had a performance status score ≤ 2 based on the
Eastern Cooperative Oncology Group (ECOG) crite-
ria, and whose laboratory results were within nor-
mal limits. Patients were excluded if they received
fewer than 6 cycles of chemotherapy, or had ab-
normal laboratory results prior to chemotherapy.
Patients who met the criteria were examined
clinically and using ultrasound (Accuvix® XQ, Me-
dison, Seoul, Korea). Some were also selectively ex-
amined using CT Scan and MRI before undergoing
debulking laparotomy or surgical staging. Chemo-
therapy were given intravenously for at least 6 cy-
cles. The dose of cisplatin was 50 mg/m2 in com-
bination with 600 mg/m2 cyclophosphamide. Car-
boplatin dose was 300 mg/m2 or AUC 6, combined
with 175 mg/m2 paclitaxel. Progression-free and
overall survival were assessed after 6 cycles of che-
motherapy by referring to patients’ medical re-
cords, direct interviews, and phone call interviews.
Adverse effects were assessed after each cycle us-
ing the National Cancer Institute (NCI) Common
Toxicity Criteria version 1. The data were statisti-
cally analyzed using Stata version 12 program (Sta-
ta Corp. LP, Texas, USA).
RESULTS
The number of epithelial ovarian cancer patients
who met the inclusion and exclusion criteria was
70 patients. The subjects were then divided into 2
groups, group A comprised of 35 (43.21%) cases
treated with cisplatin/cyclosphosphamide, and
group B comprised of 46 (56.79%) cases treated
with carboplatin/paclitaxel chemotherapy regi-
men. At the end of the study, 21 patients were
dropped out of the study, because they did not
finish six cycles of chemotherapy. Therefore, 25
patients (71.43%) in group A and 24 patients
(53.17%) in group B were accounted for analysis,
The patients recruited in this study have a ten-
dency for equally distributed characteristics bet-
ween the two groups. The costs per cycle of che-
motherapy in both groups were expectedly differ-
ent. The cost of one cycle in group A was a lot
cheaper compared to the cost in group B.
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Kaplan-Meier curve in Figure 2 shows both
groups’ survival curves. There was a significant dif-
ference between the two groups’ overall survival.
Overall survival of stage IC-IV ovarian cancer pa-
tients was 37.3 months in group A (95%CI=31.86-
43.46) and 35.5 months (95%CI=13.93-43.46) in
group B (p<0.001), as portrayed in Table 2.
Assessment of side effects was done based on
the examination table from the NCI Common Toxi-
city Criteria Version 1. Assessment after each cycle
is presented in Table 3.
Assessment of hematologic side effects includes
hemoglobin, leukocyte, and thrombocyte counts.
There were no significant differences in hematolo-
gic parameters between both groups. Statistically
significant differences were found in gastrointesti-
nal side effects. Patients in group A experienced
significantly more nausea and vomiting in compari-
son to those in group B. However, there was no
significant difference in terms of diarrhea and sto-
matitis between both groups. In the assessment of
CNS side effects, group A reported significantly
more headache than group B, but group B reported
more peripheral neuropathy.
  The number of sample meeting inclusion and exclusion  : 70 
Group A (cisplatin‐cyclosphosphamide) :  30   Group B (carboplatin‐paclitaxel):  40 
Drop out   /  did not finish six cycles of chemo:  16 Drop out  / did not finish six cycles of chemo: 5 
Accounted for analysis:  24 
At the time of data collection: 
‐Passed away: 5 
‐Lost to follow up: 3 
‐Still followed up: 16
Accounted for analysis: 25 
At the time of data collection: 
‐Passed away: 4 
‐Lost  to follow up: 9 
‐Still  followed up: 12 
Figure 1. Sample Group Based on Chemotherapy Regimen and the Last Condition of the Patient.
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Figure 2. Overall survival of group A (cisplatin/cyclosphosphamide) and group B (carboplatin/paclitaxel).
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Table 1. General Characteristics of Patients According to the Chemotherapy Treatment.
Characteristics Group A n(%) Group B n(%) p-value
Age in years (med, min-max) 44 (30-61) 52.5 (44-78) 0.0003*
Parity
0 7 (28) 6 (25)
1 6 (24) 5 (20.83) 0.911
≥2 12 (48) 13 (54.17)
Chief complaint
No complaints 1 (4) 0 (0)
Abdominal lump 21 (84) 18 (75) 0.781
Abdominal pain 1 (4) 5 (20.83)
Dyspnea 2 (8) 1 (4.17)
Performance status
0 15 (60) 20 (83.3)
1 4 (16) 2 (8.3) 0.186
2 6 (24) 2 (8.3)
Histopathology
Serous 10 (41.7) 10 (41.7)
Musinosus 4 (16) 1 (4,2) 0.484
Clear cell 7 (28) 10 (41.7)
Endometrioid 4 (16) 3 (12.5)
Tumor grade
Well-differentiated 13 (28.26) 7 (23.33)
Moderate 18 (39.13) 11 (36.67) 0.490
Undifferentiated 15 (32.61) 12 (40)
Stage
IC 1 (4) 4 (16.7)
II 3 (12) 4 (16.7) 0.458
III 17 (68) 13 (54.7)
IV 4 (16) 3 (12.5)
Stage
Early 4 (16) 8 (33.3) 0.686
Advanced 21 (84) 16 (66.7)
Time of administration
Neoadjuvant 5 (20) 4 (16.7) 0.763
Adjuvant 20 (80) 20 (83.3)
Cost per cycle (IDR) 838.787 5.532.137 <0.001*
* p-value<0.05
Table 2. Median of Overall Survival in Both Groups.
Group A
Cisplatin- Cyclosphosphamide
Group B
Carboplatin-Paclitaxel
p-value
Median of Overall Survival (month) 37.3 35.5
<0.00195%CI 31.86 -43.46 13.93-43.46
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DISCUSSION
A study conducted by McGuire et al8 found signi-
ficantly higher survival rate in ovarian cancer pa-
tients receiving CP chemotherapy than those re-
ceiving CC; 38 months (95%CI=32-44) vs 24
months (95%CI= 21-30). Piccart et al10 also found
that patients receiving CP had better survival com-
pared to those receiving CC, where the survival was
35.6 and 25.8 months, respectively. Meanwhile, our
results were contradictory to results of these pre-
vious studies, where our patients who received CC
had a significantly longer overall survival. It sug-
gests that in our sample, a combination of plati-
num-based therapy with cyclophosphamide is bet-
ter than with taxanes.
However, it is too early to conclude that cyclo-
phosphamide is better than taxanes in combination
with platinum-based chemotherapy for survival.
Our results could be by the lack of homogeneity in
our patients. The patients in group B was rela-
tively older than group A. The study counducted by
Ries et al11 discovered that the older the age of
ovarian cancer patients, the worse the prognosis or
survival. Moreover, the number of patients re-
cruited in this study was too small, with about a
third of the patients having to be excluded.
McGuire et al8 observed that the 1st, 2nd, 3rd, and
4th degree reduction of leukocytes/neutrophil ap-
peared in 4%, 9%, 22%, and 61% of patients in the
CC group, while in the CP group they appeared in
2%, 4%, 14%, and 78% of patients, respectively.
Although neutropenia of grade 3 or 4 developed in
the majority of women in the CP group, the inci-
dence of febrile neutropenia was low and was con-
sistent with the brevity of paclitaxel-induced my-
elosuppression. As for gastrointestinal symptoms,
the occurrence of toxicity according to severity (1st-
4th degree) was 8%, 42%, 8%, and 3% in the group
receiving cyclophosphamide, and 14%, 42%, 12%,
and 3% in those receiving taxanes.
Piccart et al10 found in his research that 31% of
subjects in the CC group developed 3rd grade neu-
tropenia and 40% of them developed 4th grade
neutropenia. In the CP group, 3rd and 4th grade neu-
tropenia were experienced by 32% of subjects
each. Severe nausea was more often experienced
by those in the CC group. Meanwhile, neurosensory
symptoms appeared more frequently in CP group.
In our study, neutropenia was found in 12% of
patients in group A and 18% of patients in group
B. Nausea was more commonly encountered in
group A in comparison to group B. Vomiting was
found up to three times more frequently in group
A than in group B. Furthermore, we found the
prevalence of neurosensory disturbance to be 5.3%
in group A, and 23.6% in group B (p<0.05). These
results show that compared to CC combination, CP
combination causes less gastrointestinal side ef-
fects but more hematologic and neurologic side ef-
fects. No apparent allergic reaction was observed
in both group A and group B.
CONCLUSION
Overall survival of ovarian cancer patients in this
study is better in patients receiving cisplatin-
cyclophosphamide than those receiving carbopla-
tin-paclitaxel. However, further research with a
larger sample is still needed. Gastrointestinal side
effects are more frequent in patients getting cis-
platin-cyclophosphamide, while peripheral sensory
neuropathy and hematologic side effects are found
more frequently in patients getting carboplatin-
paclitaxel chemotherapy.
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